Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis

References

• Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. J Neurooncl. 2003;5(2):104–115.
   Google Scholar
• Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood. 2010;115(24):5005–5011. doi:10.1182/blood-2009-12-258210
   PubMed Web of Science ®Google Scholar
• Khurana A, Novo M, Nowakowski GS, et al. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Adv. 2021;5(5):379–1387. doi:10.1182/bloodadvances.2020003666
   Web of Science ®Google Scholar
• Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510–522. doi:10.1182/blood-2011-03-321349
   PubMed Web of Science ®Google Scholar
• Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol. 1999;43(3):237–239. doi:10.1023/A:1006254518848
   PubMed Web of Science ®Google Scholar
• He X, Fan X, Shan Y, Ji X, Su L, Wang Y. Analysis of genomic alterations in primary central nervous system lymphoma. Medicine. 2023;102(35):e34931. doi:10.1097/MD.0000000000034931
   PubMed Web of Science ®Google Scholar
• Bertoni F, Montesinos-Rongen M. Primary diffuse large B-cell lymphoma of the central nervous system: molecular and biological features of neoplastic cells. Ann Lymphoma. 2022;6:1. doi:10.21037/aol-21-38
   Google Scholar
• Kuo HP, Ezell SA, Hsieh S, et al. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am J Cancer Res. 2016;6(11):2489.
   PubMed Web of Science ®Google Scholar
• Flanagan SE, Patch AM, Ellard S. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers. 2010;14(4):533–537. doi:10.1089/gtmb.2010.0036
   PubMed Web of Science ®Google Scholar
• Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. Pim-1 protein expression is regulated by its 5’-untranslated region and translation initiation factor elF-4E. Cell Growth Differ. 1997;8(12):1371–1380.
   PubMedGoogle Scholar
• Poulain S, Boyle EM, Tricot S, et al. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. Br J Haematol. 2015;170(2):285–287. doi:10.1111/bjh.13293
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Eng J Med. 2015;372(15):1430–1440. doi:10.1056/NEJMoa1501548
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström’s macroglobulinemia. N Eng J Med. 2015;373(6):584–586. doi:10.1056/NEJMc1506192
   PubMed Web of Science ®Google Scholar
• Lazarian G, Yin S, Hacken ET, et al. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021;39(3):380–393. doi:10.1016/j.ccell.2021.02.003
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aguilar A, Ibdaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203–5211. doi:10.1158/1078-0432.CCR-12-0845
   PubMed Web of Science ®Google Scholar
• Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget. 2014;5(13):5065. doi:10.18632/oncotarget.2080
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Tefferi A, Solberg LA, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genet Cytogenet. 1989;39(2):167–179. doi:10.1016/0165-4608(89)90182-9
   PubMedGoogle Scholar
• Rashidi A, McNeill S, Winters J, Alexander B, Roullet M. T‐cell acute lymphoblastic leukemia/lymphoma with inversion (3)(q21q26). Int J Lab Hematol. 2013;35(5):e34–e36. doi:10.1111/ijlh.12064
   PubMed Web of Science ®Google Scholar
• Iplikcioglu AC, Dinc C, Bikmaz K, Ozcan D. Primary lymphoma of the trigeminal nerve. Br J Neurosurg. 2006;20(2):103–105. doi:10.1080/02688690600682630
   PubMed Web of Science ®Google Scholar
• Akaza M, Tsunemi T, Sanjo N, Wakimoto H, Kobayashi D, Mizusawa H. Malignant lymphoma presented as left trigeminal neuralgia. Rinsho Shinkeigaku. 2009;49(7):432–436. doi:10.5692/clinicalneurol.49.432
   PubMedGoogle Scholar
• Sheng S, Sharma R, Samant R, Yuan J, Nalleballe K, Kapoor N. Isolated primary neurolymphomatosis with cranial multineuritis: a case presentation. Neurol Sci. 2021;42(3):1223–1226. doi:10.1007/s10072-020-04806-7
   PubMed Web of Science ®Google Scholar
• Jack AS, McDougall CM, Findlay JM. Primary lymphoma isolated to the trigeminal nerve. Can J Neurol Sci. 2014;41(1):103–105. doi:10.1017/S0317167100016371
   PubMed Web of Science ®Google Scholar
• Kanda T. Biology of the blood–nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry. 2013;84(2):208–212. doi:10.1136/jnnp-2012-302312
   PubMed Web of Science ®Google Scholar
• Ubogu EE. The molecular and biophysical characterization of the human blood-nerve barrier: current concepts. J Vasc Res. 2013;50(4):289–303. doi:10.1159/000353293
   PubMed Web of Science ®Google Scholar
• Malong L, Napoli I, Casal G, et al. Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery. Dev Cell. 2023;58(3):174191. doi:10.1016/j.devcel.2023.01.002
   Web of Science ®Google Scholar
• Ogiwara T, Horiuchi T, Sekiguchi N, et al. Primary malignant lymphoma of the trigeminal nerve: case report and literature review. World Neurosurg. 2015;84(2):592. e3–592. e7. doi:10.1016/j.wneu.2015.03.019
   PubMed Web of Science ®Google Scholar
• Abdel Aziz KM, van Loveren HR. Primary lymphoma of Meckel’s cave mimicking trigeminal schwannoma: case report. Neurosurgery. 1999;44(4):859–862. doi:10.1097/00006123-199904000-00096
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Izumoto S, Oshino S, et al. Primary malignant lymphoma of the trigeminal region treated with rapid infusion of high-dose MTX and radiation: case report and review of the literature. Surg Neurol. 2003;60(4):343–348. doi:10.1016/S0090-3019(02)01046-7
   PubMedGoogle Scholar
• Bulsara KR, Kadri PA, Husain M, Al-Mefty O. Malignant lymphoma of the trigeminal region. Case illustration. J Neurooncol. 2005;73(3):279–280. doi:10.1007/s11060-004-5951-1
   PubMed Web of Science ®Google Scholar
• Perera C, Fitt G, Kalnins R, Lee S, Gonzalvo A. Lymphoma of the trigeminal nerve–the need for histological diagnosis. Br J Neurosurg. 2014;28(2):278–280. doi:10.3109/02688697.2013.835374
   PubMed Web of Science ®Google Scholar
• Sakai N, Ito-Yamashita T, Takahashi G, et al. Primary neurolymphomatosis of the lower cranial nerves presenting as dysphagia and hoarseness: a case report. J Neurol Surg Rep. 2014;75(01):e62–e66. doi:10.1055/s-0033-1363505
   PubMedGoogle Scholar
• Sato H, Hiroshima S, Anei R, Kamada K. Primary neurolymphomatosis of the trigeminal nerve. Br J Neurosurg. 2023;37(4):697–700. doi:10.1080/02688697.2019.1568391
   PubMedGoogle Scholar
• Koerbel A, Roser F, Psaras T, Beschorner R, Tatagiba M. Primary non-Hodgkin lymphoma of the cranial nerves mimicking neurofibromatosis Type 2: case illustration. J Neurosurg. 2005;102(6):1166. doi:10.3171/jns.2005.102.6.1166
   PubMed Web of Science ®Google Scholar